Form 8-K · Current report
Solventum 8-K, filed Nov 5, 2026
- Filed
- CIK
- 0001964738
- Accession no.
- 0001964738-26-000055
Summary
Solventum reported third-quarter 2026 sales of $1.9 billion, down 7.0% on a reported basis and 2.8% organically, and raised its full-year 2026 adjusted earnings-per-share guidance to $7.20–$7.30 while expecting organic sales growth toward the high end of its +2.5% to +3.0% range. CEO Bryan Hanson attributed the quarter's results to every segment contributing as the company completed its largest ERP cutover, and Solventum said its separation from 3M is more than 90% complete.
Key points
- Third-quarter 2026 sales were $1.9 billion, down 7.0% reported and 2.8% organic, with the organic decline reflecting the expected 630 basis point reversal of second-quarter advance orders placed ahead of an ERP system cutover.
- GAAP diluted earnings per share were $(0.07) and adjusted diluted earnings per share were $1.45, down 3.6%.
- Full-year 2026 adjusted EPS guidance was raised to $7.20–$7.30 from $7.10–$7.20, with organic sales growth expected toward the high end of the +2.5% to +3.0% range and free cash flow affirmed at $200–$300 million.
- Solventum received FDA 510(k) clearance for combined use of Restrata and V.A.C. Therapy, said separation from 3M is more than 90% complete, and exited roughly 90% of 3M transition service agreements.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition On November 5, 2026, Solventum issued a press release reporting third-quarter 2026 financial results (attached hereunder as Exhibit 99.1 and incorporated herein by reference). Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press Release, dated as of November 5, 2026, of Solventum Corporation (furnished pursuant to Item 2.02 hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). Exhibit 99.1: EX-99.1 2 q32026-8kerexx991.htm EX-99.1 Exhibit 99.1 Solventum Reports Third Quarter 2026 Financial Results •Reported sales decreased 7.0%; …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.